Recent investigations have converged on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine communication. While GCGR activators are commonly employed for addressing type 2 T2DM, their unexpected consequences on reward circuits, specifically influenced by dopaminergic systems, ar